A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Recruiting · Phase 1, Phase 2 · NCT06481306
Conditions: Anemia, Sickle Cell, Healthy Volunteers
At a glance
- Research payments reported, 2025
- $25,050
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 224
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986470 (drug), Placebo (drug), Famotidine (drug), Pantoprazole (drug)
- Dates
- Started 2024-07-17; completion 2027-11-16
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
From ClinicalTrials.gov, last updated 2026-08-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $25,050 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Elizabeth S. Klings, M.D. Pulmonology · Boston, MA
- Cecelia L. Calhoun, MD Pediatric Hematology & Oncology · Saint Louis, MO
- Sanaa Rizk, MD Hematology · Philadelphia, PA
- Sheinei S. Alan, MD, PHD Internal Medicine · Fairfax, VA
- Wally R. Smith, M.D. Internal Medicine · Richmond, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Smilow Hospital Cancer Center at Yale New Haven $7,860
- Inova Loudoun Hospital, VA $4,820
- University Gastroenterology and Hepatology $4,207
- University of Alabama Hospital, AL $3,750
- Virginia Commonwealth University $2,436
- Boston Medical Center, MA $1,978
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.